Lead Investigator: Toby Pillinger, King’s College London
Title of Proposal Research: Physiological effects of acute antidepressant treatment in psychiatric disorders: a systematic review and network meta-analysis
Vivli Data Request: 10406
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Background
Antidepressants are effective medications for common mental health conditions such as depression. However, antidepressants often cause side-effects, for example causing weight gain and changes in blood pressure. There are over 30 different antidepressants available, and we know that some groups of antidepressants vary in terms of the physical side-effects they can cause. However, at the moment it is not clear which specific antidepressants are better or worse for different physical side-effects.
Necessity of the research
It will be helpful for us to know which antidepressants are better/worse at causing physical health side effects, as this will help doctors and patients choose the medication that suits them best.
How the research will be conducted
We will conduct a research study called a ‘network meta-analysis’. Network meta-analysis combines the results of multiple other studies, that have each looked at the effects of different antidepressants. The result of network meta-analysis is a ‘league table’ that ranks antidepressants from best to worst for risk of different side-effects.
Requested Studies:
An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder
Data Contributor: GlaxoSmithKline
Study ID: NCT00048204
Sponsor ID: NKD20006
Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily
Data Contributor: GlaxoSmithKline
Study ID: PAR 29060.309 HP/81/162A
Sponsor ID: PAR 29060.309 HP/81/162A
A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression
Data Contributor: GlaxoSmithKline
Study ID: 29060/448
Sponsor ID: 29060/448
A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent.
Data Contributor: GlaxoSmithKline
Study ID: BRL-29060/109
Sponsor ID: BRL-29060/109
A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo
Data Contributor: GlaxoSmithKline
Study ID: 29060/276
Sponsor ID: 29060/276
A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients
Data Contributor: GlaxoSmithKline
Study ID: 29060/487
Sponsor ID: 29060/487
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg – 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg – 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.
Data Contributor: GlaxoSmithKline
Study ID: AK130939
Sponsor ID: AK130939
A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg – 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg – 150mg once daily) and Placebo in Subjects with Major Depressive Disorder.
Data Contributor: GlaxoSmithKline
Study ID: WXL101497
Sponsor ID: WXL101497
Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder
Data Contributor: Lilly
Study ID: NCT00062673
Sponsor ID: 6091
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder
Data Contributor: Lilly
Study ID: NCT00067912
Sponsor ID: 7999
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder
Data Contributor: Lilly
Study ID: NCT00071695
Sponsor ID: 6090
Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression
Data Contributor: Lilly
Study ID: NCT00073411
Sponsor ID: 7978
Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression
Data Contributor: Lilly
Study ID: NCT00406848
Sponsor ID: 10815
Duloxetine Versus Paroxetine in the Acute Treatment of Major Depression
Data Contributor: Lilly
Study ID: NCT00489775
Sponsor ID: 6937
Duloxetine Once-Daily Dosing Versus Placebo in the Acute Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMBH(A)
Sponsor ID: F1J-MC-HMBH(A)
Duloxetine Once-Daily Dosing Versus Placebo in the Acute Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMBH(B)
Sponsor ID: F1J-MC-HMBH(B)
Duloxetine Versus Placebo and Paroxetine in the Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMAY(A)
Sponsor ID: F1J-MC-HMAY(A)
Duloxetine Versus Placebo in the Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMAQ(A)
Sponsor ID: F1J-MC-HMAQ(A)
Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMAT(A)
Sponsor ID: F1J-MC-HMAT(A)
Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMAT(B)
Sponsor ID: F1J-MC-HMAT(B)
Duloxetine Versus Placebo and Paroxetine in the Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMAY(B)
Sponsor ID: F1J-MC-HMAY(B)
Duloxetine Versus Placebo in the Treatment of Major Depression
Data Contributor: Lilly
Study ID: F1J-MC-HMAQ(B)
Sponsor ID: F1J-MC-HMAQ(B)
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT01140906
Sponsor ID: 13267A
Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT00839423
Sponsor ID: 11492A
An Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study on the Efficacy of Vortioxetine Versus Escitalopram on Cognitive Dysfunction in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT02272517
Sponsor ID: 15907A
A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT00596817
Sponsor ID: 11985A
A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment
Data Contributor: Lundbeck
Study ID: NCT01488071
Sponsor ID: 14178A
A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT00635219
Sponsor ID: 11984A
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose Study on the Efficacy of [Vortioxetine] Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD)
Data Contributor: Lundbeck
Study ID: NCT01422213
Sponsor ID: 14122A
Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries
Data Contributor: Lundbeck
Study ID: NCT01571453
Sponsor ID: 13926A
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT02279966
Sponsor ID: 15906A
Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients
Data Contributor: Lundbeck
Study ID: NCT00811252
Sponsor ID: 12541A
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Data Contributor: Lundbeck
Study ID: NCT02709746
Sponsor ID: 12710A
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
Data Contributor: Lundbeck
Study ID: NCT02279953
Sponsor ID: 15905A
A Randomised, Double-blind, Parallel-group, Active Controlled Study Evaluating the Efficacy of Vortioxetine Versus Desvenlafaxine in Adult Patients Suffering From Major Depressive Disorder With Partial Response to SSRI Treatment
Data Contributor: Lundbeck
Study ID: NCT04448431
Sponsor ID: 18498A
99067 Montgomery SA, Huusom AKT, Bothmer J. A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder. Neuropsychobiology. 2004;50(1):57-64
Data Contributor: Lundbeck
A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder
Data Contributor: Pfizer Inc.
Study ID: NCT01121484
Sponsor ID: 3151A1-3364
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder
Data Contributor: Pfizer Inc.
Study ID: NCT00063206
Sponsor ID: 3151A1-304
A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder
Data Contributor: Pfizer Inc.
Study ID: NCT00369343
Sponsor ID: 3151A1-403
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release
Data Contributor: Pfizer Inc.
Study ID: NCT00824291
Sponsor ID: 3151A1-4415
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder
Data Contributor: Pfizer Inc.
Study ID: NCT00863798
Sponsor ID: 3151A1-3362
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder
Data Contributor: Takeda
Study ID: NCT00730691
Sponsor ID: LuAA21004_308
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction
Data Contributor: Takeda
Study ID: NCT01364649
Sponsor ID: LuAA21004_318
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01153009
Sponsor ID: LuAA21004_315
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)
Data Contributor: Takeda
Study ID: NCT01564862
Sponsor ID: LuAA21004_202
A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects
Data Contributor: Takeda
Study ID: NCT02932904
Sponsor ID: Vortioxetine-4001
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT02371980
Sponsor ID: LuAA21004_402
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Once Daily Oral Lu AA21004 in Patients With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT02389816
Sponsor ID: LuAA21004/CCT-004
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01179516
Sponsor ID: LuAA21004_317
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT00672958
Sponsor ID: LuAA21004_303
A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Effects of Oral Administration of Lu AA21004 20 mg on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects
Data Contributor: Takeda
Study ID: NCT01299805
Sponsor ID: LuAA21004_124
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder
Data Contributor: Takeda
Study ID: NCT00731120
Sponsor ID: LuAA21004_309
A Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT00735709
Sponsor ID: LuAA21004_305
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder
Data Contributor: Takeda
Study ID: NCT00734071
Sponsor ID: LuAA21004_310
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder
Data Contributor: Takeda
Study ID: NCT00744627
Sponsor ID: LuAA21004_311
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01255787
Sponsor ID: LuAA21004/CCT-002
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT00672620
Sponsor ID: LuAA21004_304
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01163266
Sponsor ID: LuAA21004_316
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder
Data Contributor: Takeda
Study ID: NCT01355081
Sponsor ID: LuAA21004/CCT-003